Federation Des Caisses Desjardins Du Quebec Merus N.V. Transaction History

Federation Des Caisses Desjardins Du Quebec

$18.9 Billion
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 14, 2024	SELL	$13.98 - $29.25 $9,925 - $20,767	-710 Closed	0 $0
Q1 2022 Aug 14, 2024	BUY	$23.58 - $30.91 $16,741 - $21,946	710 New	710 $18.8 Million
Q4 2021 Aug 30, 2024	SELL	$20.0 - $32.29 $82,600 - $133,357	-4,130 Reduced 58.52%	2,927 $93 Million
Q2 2021 Aug 30, 2024	BUY	$20.0 - $25.48 $141,140 - $179,812	7,057 New	7,057 $149 Million

Others Institutions Holding MRUS

# of Institutions

200

Shares Held

61.9M

Call Options Held

243K

Put Options Held

300K

Rtw Investments, LP New York, NY

4.17M
Shares

$174 Million
3.32% of portfolio
Deerfield Management Company, L.P. (Series C) New York, NY

3.41M
Shares

$143 Million
3.17% of portfolio
Commodore Capital LP New York, NY

3.35M
Shares

$140 Million
14.22% of portfolio
Wellington Management Group LLP Boston, MA

2.89M
Shares

$121 Million
0.03% of portfolio
Samlyn Capital, LLC New York, NY

2.61M
Shares

$109 Million
2.1% of portfolio

View Full List

About Merus N.V.

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $1.92B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

More about MRUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account